M
Markus Theurl
Researcher at Innsbruck Medical University
Publications - 48
Citations - 1588
Markus Theurl is an academic researcher from Innsbruck Medical University. The author has contributed to research in topics: Secretoneurin & Angiogenesis. The author has an hindex of 18, co-authored 44 publications receiving 1073 citations.
Papers
More filters
Journal ArticleDOI
Cardiopulmonary recovery after COVID-19: an observational prospective multicentre trial
Thomas Sonnweber,Sabina Sahanic,Alex Pizzini,Anna Luger,Christoph Schwabl,Bettina Sonnweber,Katharina Kurz,Sabine Koppelstätter,David Haschka,Verena Petzer,Anna Boehm,Magdalena Aichner,Piotr Tymoszuk,Daniela Lener,Markus Theurl,Almut Lorsbach-Köhler,Amra Tancevski,Anna Schapfl,Marc Schaber,Richard Hilbe,Manfred Nairz,Bernhard Puchner,Doris Hüttenberger,Christoph Tschurtschenthaler,Malte Aßhoff,Andreas Peer,Frank Hartig,Romuald Bellmann,Michael Joannidis,Can Gollmann-Tepeköylü,Johannes Holfeld,Gudrun Feuchtner,Alexander E. Egger,Gregor Hoermann,Andrea Schroll,Gernot Fritsche,Sophie Wildner,Rosa Bellmann-Weiler,Rudolf Kirchmair,Raimund Helbok,Helmut Prosch,Dietmar Rieder,Zlatko Trajanoski,Florian Kronenberg,Ewald Wöll,Günter Weiss,Gerlig Widmann,Judith Löffler-Ragg,Ivan Tancevski +48 more
TL;DR: A relevant percentage of post-CO VID-19 patients presented with persisting symptoms and lung function impairment along with radiological pulmonary abnormalities >100 days after the diagnosis of COVID-19, however, results indicate a significant improvement in symptoms and cardiopulmonary status over time.
Journal ArticleDOI
Persisting alterations of iron homeostasis in COVID-19 are associated with non-resolving lung pathologies and poor patients' performance: a prospective observational cohort study.
Thomas Sonnweber,Anna Boehm,Sabina Sahanic,Alex Pizzini,Magdalena Aichner,Bettina Sonnweber,Katharina Kurz,Sabine Koppelstätter,David Haschka,Verena Petzer,Richard Hilbe,Markus Theurl,Daniela Lehner,Manfred Nairz,Bernhard Puchner,Anna Luger,Christoph Schwabl,Rosa Bellmann-Weiler,Ewald Wöll,Gerlig Widmann,Ivan Tancevski,Judith-Löffler-Ragg,Günter Weiss +22 more
TL;DR: In this article, a prospective, multicentre, observational CovILD cohort study (ClinicalTrials.gov number, NCT04416100), which systematically follows up patients after severe coronavirus disease 2019 (COVID-19) is frequently associated with hyperinflammation and hyperferritinemia.
Journal ArticleDOI
Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site
Emir Hadzijusufovic,Emir Hadzijusufovic,Karin Albrecht-Schgoer,Kilian Huber,Gregor Hoermann,Florian Grebien,Gregor Eisenwort,Wilfried Schgoer,Susanne Herndlhofer,Christoph Kaun,Markus Theurl,Wolfgang R. Sperr,Uwe Rix,Irina Sadovnik,Bernd Jilma,Gerit-Holger Schernthaner,Johann Wojta,Dominik Wolf,Giulio Superti-Furga,Rudolf Kirchmair,Peter Valent +20 more
TL;DR: Together, Nilotinib exerts direct pro-atherogenic and anti-angiogenic effects on vascular endothelial cells, which may contribute to development of AOD in patients with CML.
Journal ArticleDOI
The Neuropeptide Catestatin Acts As a Novel Angiogenic Cytokine via a Basic Fibroblast Growth Factor–Dependent Mechanism
Markus Theurl,Wilfried Schgoer,Karin Albrecht,Johannes Jeschke,Margot Egger,Arno Beer,Danijela Vasiljevic,Song Rong,Anna Maria Wolf,Ferdinand H. Bahlmann,Josef R. Patsch,Dominik Wolf,Peter Schratzberger,Sushil K. Mahata,Rudolf Kirchmair +14 more
TL;DR: Catestatin acts as a novel angiogenic cytokine via a basic fibroblast growth factor–dependent mechanism, indicating induction of arteriogenesis and postnatal vasculogenesis.
Journal ArticleDOI
The Angiogenic Factor Secretoneurin Induces Coronary Angiogenesis in a Model of Myocardial Infarction by Stimulation of Vascular Endothelial Growth Factor Signaling in Endothelial Cells
Karin Albrecht-Schgoer,Wilfried Schgoer,Johannes Holfeld,Markus Theurl,Dominik Wiedemann,Christina Maria Steger,Rajesh Gupta,Severin Semsroth,Reiner Fischer-Colbrie,Arno Beer,Ursula Stanzl,Eva Huber,Sol Misener,Daniel Dejaco,Raj Kishore,Otmar Pachinger,Michael Grimm,Nikolaos Bonaros,Rudolf Kirchmair +18 more
TL;DR: In vivo findings indicate that secretoneurin may be a promising therapeutic tool in ischemic heart disease by enhancing binding of VEGF to low-affinity binding sites and neuropilin-1 and stimulates further growth factor receptors like fibroblast growth factor receptor-3.